Navigation Links
FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis
Date:1/31/2012

lydeco was approved ahead of the drug's April 18, 2012, prescription user fee goal date and is designated as an orphan drug, which identifies the disease as affecting fewer than 200,000 people in the United States.

In patients with the G551D mutation, Kalydeco, a pill taken two times a day with fat-containing food, helps the protein made by the CFTR gene function better and as a result, improves lung function and other aspects of CF such as increasing weight gain.

"Kalydeco is the first available treatment that targets the defective CFTR protein, which is the underlying cause of cystic fibrosis," said Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research. "This is a breakthrough therapy for the cystic fibrosis community because current therapies only treat the symptoms of this genetic disease."

Two 48-week, placebo-controlled clinical studies involving 213 patients, one in patients ages 12 years and older and another in patients ages 6 years to 11 years, were used to evaluate the safety and efficacy of Kalydeco in CF patients with the G551D mutation. In both studies, treatment with Kalydeco resulted in significant and sustained improvement in lung function.

Kalydeco is effective only in patients with CF who have the G551D mutation. It is not effective in CF patients with two copies of the F508 mutation in the CFTR gene, which is the most common mutation that results in CF. If a patient's mutation status is not known, an FDA-cleared CF mutation test should be used to determine whether the G551D mutation is present.

The most common side effects of Kalydeco include upper respiratory tract infection, headache, stomach ache, rash, diarrhea, and dizziness.

Kalydeco is manufactured by Vertex Pharmaceuticals Inc. of Cambridge, Mass.

For more information:

FDA Voice Blog: How science and collaboration led to a new, "personalized" cystic fibrosis treatment for some patients

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Research and Markets ... of the "Global Gynecological Devices Market ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... wide categories based on their operations. These ... different gynecological conditions that affect the female ...
(Date:9/19/2014)... TRIANGLE PARK, N.C. , Sept. 19, 2014 ... focused on cloud-based drug design and development, partnering ... The company,s mission is to design new drugs ... 1 and 2 partners to further their development. ... its portfolio investments. To support this business model, ...
(Date:9/19/2014)... , Sept. 19, 2014 The American Association ... Medical Design and Manufacturing has joined the AAHomecare Corporate ... Harvey Diamond have been actively involved in ... as it has quickly grown into a major global ... like Drive allows AAHomecare to increase efforts on behalf ...
Breaking Medicine Technology:Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2
... Inc. (NASDAQ: DCTH ) announced today that management ... Conference on Tuesday, August 16, 2011 at 2:25 P.M. ET ... an overview of the Company,s business strategy and recent corporate ... invitation only. Delcath will offer a live audio webcast of ...
... 10, 2011 Leading events organizers UBM Canon ... (LSE: UBM), today announced a virtual conference event which will examine ... chain, counterfeit drugs. Titled ,Pharmaceutical Track & Trace Authentication: The Fight ... from 6:00 to 14:00 New York time, 12:00 to 20:00 Paris ...
Cached Medicine Technology:Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011 2Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011 3UBM Canon Introduces a Compelling New Virtual Conference Focused on Track & Trace Solutions for the Pharma Sector 2UBM Canon Introduces a Compelling New Virtual Conference Focused on Track & Trace Solutions for the Pharma Sector 3
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- The U.S. Food and Drug ... Thursday. Trulicity is part of a class of once-a-week injectable ... type 2 diabetes. "Trulicity is a new treatment ... treatment regimens to control blood sugar levels in the overall ... of the FDA,s Office of Drug Evaluation II, said in ...
(Date:9/19/2014)... cells to treat and cure disease is a ... hindered by the inability of doctors and scientists to ... cells in patients without resorting to invasive procedures, like ... in the online journal Magnetic Resonance in Medicine ... School of Medicine, University of Pittsburgh and elsewhere describe ...
(Date:9/19/2014)... Recent two-generation approaches to reducing poverty that help ... from researchers, advocates, and foundations. By combining education ... move to jobs that offer a path out ... for children, these programs aim to improve the ... a new report from the National Center for ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- More states are ... medication epinephrine to use for any child having a ... treatment for "anaphylaxis," an allergic reaction that can lead ... blood pressure and even death. In people ... or tree nuts, insect venom or certain drugs, anaphylaxis ...
(Date:9/19/2014)... 19, 2014 Top 10 Best ... announced that HostGator.com, GoDaddy and Bluehost are among ... companies are the most recommended suppliers for webmasters ... to buy high quality Linux hosting (including VPS ... is one of many top hosting companies that ...
Breaking Medicine News(10 mins):Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:A better way to track emerging cell therapies using MRIs 2Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3Health News:Top10BestSEOHosting.com Announces Great Linux Web Hosting Suppliers In 2014 2
... REMIND LAWMAKERS CALIFORNIA PREMIUMS ARE 17 PERCENT ... ... At the Assembly,Health Committee,s hearing on Governor Arnold Schwarzenegger,s health ... National Association of Insurance and Financial Advisors-California,(NAIFA-California) urged lawmakers to ...
... 31 Conseco, Inc. (NYSE:,CNO) today reported results for ... reflect a number of significant events, as,progress on our ... increasingly evident," CEO Jim Prieur said. "We saw continued,strong ... businesses, while,Conseco Insurance Group, even with a decline in ...
... Effective ... Alternatives, LOS ... thinking about health and medicine over the past few years as ... As concerns grow regarding conventional, over-the-counter,medicine, Hyland,s homeopathic medicines offer a ...
... Dr. James M. Farrell, a,doctor of chiropractic practicing ... Chiropractic Association (CCA). He was nominated,and chosen by his ... the CCA since 1992, Dr. Farrell has been extremely ... a committee chair, board member,and executive board member prior ...
... Today researchers report a newly identified genetic ... cancer in African American men. This study, which ... prostate cancer in high-risk populations, is published online in ... cancer is the second leading cause of cancer death ...
... feline DNA could help humans, too, scientists say , WEDNESDAY, ... of the domestic cat ( Felis catus ), an advance ... pets and provide an excellent model for human disease. , ... traced back several generations to Sweden, was the subject of ...
Cached Medicine News:Health News:Health Insurance Agents Warn Against Imposing a 'Health Care Reform' Tax in California 2Health News:Health Insurance Agents Warn Against Imposing a 'Health Care Reform' Tax in California 3Health News:Conseco Reports Third Quarter Results 2Health News:Conseco Reports Third Quarter Results 3Health News:Conseco Reports Third Quarter Results 4Health News:Conseco Reports Third Quarter Results 5Health News:Conseco Reports Third Quarter Results 6Health News:Conseco Reports Third Quarter Results 7Health News:Conseco Reports Third Quarter Results 8Health News:Conseco Reports Third Quarter Results 9Health News:Conseco Reports Third Quarter Results 10Health News:Conseco Reports Third Quarter Results 11Health News:Conseco Reports Third Quarter Results 12Health News:Conseco Reports Third Quarter Results 13Health News:Conseco Reports Third Quarter Results 14Health News:Conseco Reports Third Quarter Results 15Health News:Conseco Reports Third Quarter Results 16Health News:Conseco Reports Third Quarter Results 17Health News:Hyland's Inc. Reports More Consumers Turn to Homeopathic Medicines to Fight Illness at Home 2Health News:Golden Doctor of Chiropractic Elected President of the Colorado Chiropractic Association 2Health News:Scientists discover genetic variant associated with prostate cancer in African Americans 2
Sprint Quattro Secure™ is a Steroid-Eluting, True Bipolar, Active Fixation ICD Lead....
The Livewire steerable electrophysiology catheter is uniquely designed with an ergonomic handle and patented steering mechanism to provide smooth, precise catheter tip movement, even during lengthy e...
The Livewire cannulator offers improved access to the coronary sinus by combining the ergonomic Livewire steering mechanism with numerous specialized features....
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
Medicine Products: